Scale Your Cell Therapy Process Faster, More Robustly & at Lower Cost

Streamline End-to-End Process Development through AI, Automation & Vendor Management to Deepen Therapeutic Understanding, Improve Speed & Reduce Costs

The Pressure on Cell Therapy Process Development Has Never Been Higher.

Last year, the FDA published over 200 Complete Response Letters. The pattern was clear: most cell therapy rejections stem from CMC, comparability, and manufacturing readiness. Meanwhile, the number cell therapies in the clinic has increased by 13% from 2024 to 2025. This has led to growing pressures to move programs toward the next clinical stage and commercialization.

The science is working, but the processes need to catch up.

That's why the 5th Process Development & Automation for Cell Therapies Summit returns in 2026 - this time in San Diego.

Bringing together Process Development, Analytical Development, QC, and MSAT leaders from early clinical to commercial stage, this is the only industry-led event dedicated exclusively to the process development and automation challenges determining whether your therapy reaches patients.

What's different this year:

New west coast perspectives: from a fresh pool of San Diego's clinical-stage cell therapy companies joining an established community for the first time.
Deeper automation focus: reflecting industry demand to learn how leading teams are reducing manual processes, aggregating manufacturing data, and scaling without sacrificing quality.
Increase Late Stage & Pharma Perspectives: from Bristol Myers Squibb, Regeneron, AstraZeneca and others to support your team with examples of how to reach your next clinical or commercial stage.

Download the Agenda

Implementing Machine Learning & Digital Technologies to Optimize Process Development Workflows & Predict Manufacturing Outcomes

Workshop A - Implementing Machine Learning & Digital Technologies to Optimize Process Development Workflows & Predict Manufacturing Outcomes

Workshop B - Bridging the Healthy & Patient Starting Material Gap for Robust Process Development & Ensuring Manufacturing Robustness

Ensuring Comparability Across Clinical Phases to Achieve Commercial Success with Relma-cel CAR-T Therapy

Panel Discussion: Implementing Automation in Process Development While Maintaining Critical Quality Attributes & Product Consistency Across Manufacturing Scales

Attending Companies Include

Explore the Full Event Guide

Hear from 18+ expert speakers covering the full cell therapy development pipeline from early clinical to commercial.
Gain 6+ hours of late and commercial stage presentations and panel discussions you can apply immediately.
Connect and network with 30% of speakers from Top 20 global biopharma companies.
65:35 autologous to allogeneic content split across two days.
Gain the opportunity to join exclusive roundtables on in vivo cell therapy process development to showcase how the process will adapt to future advances.

Download the Agenda